Research Article

Rapid Production of Human VEGF-A following Intradermal Injection of Modified VEGF-A mRNA Demonstrated by Cutaneous Microdialysis in the Rabbit and Pig In Vivo

Susanne Pehrsson,1 Mikko Hölttä,2 Gunilla Linhardt,1 Regina Fritsche Danielson,3 and Leif Carlsson

1Bioscience Heart Failure, Cardiovascular Renal and Metabolism, IMED Biotech Unit AstraZeneca Gothenburg, Sweden
2IMED Biotech Unit, Drug Safety and Metabolism, Mechanistic Safety and ADME Sciences, AstraZeneca R&D, Gothenburg, Sweden
3Cardiovascular, Renal and Metabolism, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden

Correspondence should be addressed to Leif Carlsson; leif.g.carlsson@astrazeneca.com

Received 26 September 2018; Accepted 2 January 2019; Published 15 January 2019

Academic Editor: Kibret Mequanint

Copyright © 2019 Susanne Pehrsson et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Chemically modified mRNA is a novel, highly efficient, biocompatible modality for therapeutic protein expression that may overcome the challenges and safety concerns with current gene therapy strategies. We explored the efficiency of intradermally injected modified VEGF-A mRNA (VEGF-A mRNA) formulated in a biocompatible citrate/saline buffer to locally produce human VEGF-A protein. Rabbits (n=4) and minipigs (n=3) were implanted with subcutaneous microdialysis probes close to the injection sites and interstitial-fluid samples and skin biopsies were analysed for production of VEGF-A protein over time for up to 8 hours. Three to 4 hours after the intradermal injection of VEGF-A mRNA, detectable levels of human VEGF-A protein were seen in the microdialysis eluates in both species. In the pig, the VEGF-A concentrations increased dose-dependently reaching a maximum 6 hours after dosing (62.7±28.4, 357.6±240.6, and 746.3±210.2 pg/mL following injection of 24, 120, and 600 μg VEGF-A mRNA, respectively). Likewise, in tissue biopsies harvested at study end (8 hours after VEGF-A mRNA injection), the content of VEGF-A protein increased dose-dependently. In contrast, VEGF-A protein was not detected in eluates originating from sites injected with citrate/saline vehicle. It is concluded that intradermal injection of VEGF-A mRNA is associated with a rapid and local production of VEGF-A protein. Considering the pro-angiogenic effect of VEGF-A, VEGF-A mRNA may hold promise for regenerative treatment of patients with diabetic wounds and ischemic cardiovascular disease.

1. Introduction

Through stimulation of angiogenesis, arteriogenesis, and lymphangiogenesis, therapeutic vascular growth is emerging as a concept for management of vascular indications such as coronary and limb ischemia and chronic wounds [1]. The vascular endothelial growth factor (VEGF) family members are key regulators of vascular growth and VEGF-A administered as recombinant protein or via gene transfer has received much attention for its potential beneficial effects in cardiovascular medicine. However, randomized controlled trials have not lived up to expectations and evidence of clinical efficacy is inconclusive. The reason(s) for the lack of clinical benefit is currently somewhat unclear but may include factors such as suboptimal pharmacokinetics and local concentrations of the protein, poor gene transfer efficiency, inappropriate dosing, and regression of immature vessels as well as growth factor-related adverse effects and prolonged expression of the paracrine factor. To circumvent the issues associated with recombinant protein and gene transfer modalities, synthetic and chemically modified mRNA has been put forward as a non-immunogenic and non-integrating modality for transient expression of proteins in mammalian cells [2–4]. However, prior in vivo work with modified VEGF-A mRNA

Hindawi
BioMed Research International
Volume 2019, Article ID 3915851, 7 pages
https://doi.org/10.1155/2019/3915851
(VEGF-A mRNA) therapies has relied on cationic lipid carriers and non-optimized mRNA transcript production methods that may cause infusion-related hypersensitivity reactions, can be associated with tissue injury, and promote RNA degradation via modulation of the local innate immune system [5]. Recent observations indicate, however, that, by direct injection in cardiac and skeletal muscle, local delivery of modified mRNA formulated simply in citrate-buffered saline may result in sustained and efficient transfection of the mRNA [6–8]. Hence, in mouse, rat, and pig models of myocardial infarction, intramyocardial injection of VEGF-A mRNA led to elevated cardiac VEGF-A protein levels and improved heart function and survival, which were associated with improved formation of new blood vessels around the infarct [6, 7]. Furthermore, when given intradermally in a mouse ear model, VEGF-A mRNA induced vasodilation, blood flow increase, capillary angiogenesis, and neovascularization [9]. Prompted by these encouraging experimental findings, VEGF-A mRNA is currently undergoing clinical testing in type 2 diabetic patients and in patients undergoing coronary artery by-pass grafting [10–12]. The present series of in vivo experiments is the first to demonstrate that intradermal injection of VEGF-A mRNA formulated in a biocompatible buffer results in local production of human VEGF-A protein as demonstrated via serial interstitial-fluid sampling and analysis of eluates from cutaneous inserted microdialysis probes.

2. Materials and Methods

2.1. Preparation of Rabbits for Drug Administration and Microdialysis. Four male New Zealand White rabbits (2.4–3.0 kg body weight, Liddköpings rabbit farm, Sweden) were anaesthetised with ketamine (5 mg/kg, Ketalar®, Pfizer AB, Sollentuna, Sweden) and medetomidine (0.15 mg/kg, Domitor®, Orion Pharma, Espoo, Finland) administered as an intravenous bolus injection followed by a maintenance infusion (11 and 0.33 mg/kg•h), respectively. The rabbits were intubated and artificially ventilated with a mixture of room air and 10% O₂ with a Servo ventilator (900D, Siemens Elema, Solna, Sweden). The respiratory rate was kept constant at 30 cycles/min. Before and during the experiment, the blood gases and pH in arterial blood were measured by a blood gas analyzer (ABL800 Flex, Radiometer, Copenhagen, Denmark) and, if necessary, adjusted to fall within normal physiological ranges for rabbits by adjusting the tidal volume. The rectal temperature was kept between 38 and 39.5° C by covering the animals and by external heating.

A percutaneous polyethylene catheter (Venflon 0.8 mm, Viggo, Helsingborg, Sweden) for administration of anaesthetics was inserted into a marginal vein on the left ear. A polyethylene catheter (Intramedic PE-90 Clay Adams, Becton Dickinson, Sparks, MD, USA) was inserted into the right carotid artery for arterial blood pressure recording (by means of a pressure transducer, Peter von Berg Medizintechnik GmbH, Kirchseeon/Englharting, Germany) and for blood sampling, respectively. Signals from blood pressure measurements were recorded and sampled by using a computer and software (PharmLab V6.6, AstraZeneca R&D Mölndal, Sweden). The fur on the left hind leg was removed with an electric razor.

Two 100 kDa linear microdialysis probes, named A and B in each experiment (66 linear catheter & 66 high cut off linear catheter, M Dialysis AB, Hammarby, Stockholm, Sweden), were inserted id on the upper part of the left hind leg of the rabbit according to the instructions provided by the supplier. The microdialysis probes were perfused with 0.5 μL/min physiological saline (9 mg/mL, Fresenius Kabi AG, Bad Homburg, Germany) and the eluate samples were collected on ice in pre-weighed 0.5 mL tubes (Protein LoBind, Eppendorf AG, Hamburg, Germany). Dead space between the dialysis membrane and the collection tube outlet was about 1.5 μL. The volume of each eluate was determined and 2% bovine serum albumin (BSA, A7979, Sigma-Aldrich, St. Louis, MO, USA) in phosphate buffered saline (PBS pH 7.4, gibco® by life technologies™, Paisley, UK) was added at 1:1 conditions. The samples were stored at -80° C until analyzed.

The experimental design is illustrated in Figure 1. At t=0 h, the recovery period for both microdialysis probes was started. One hour later (i.e., t=1 h), recovery eluate was collected and subsequently 4 intradermal injections of VEGF-A mRNA formulated in citrate/saline buffer (10 mmol/L/130 mmol/L, pH 6.5) at the microdialysis-probe sites were given as depicted in Figure 2. Protein-containing eluate was collected every hour from t=2 h to t=6 h and handled as described above. At study end, the animals were terminated by a lethal iv dose of pentobarbital sodium (Allfatal vet, Omnidea AB, Stockholm, Sweden).
Microdialysis, VEGF-A eluate collected every 60 min

Figure 1: Experimental flow chart in the rabbit study. For further details, see methods.

VEGF-A eluate VEGF-A eluate VEGF-A eluate VEGF-A eluate VEGF-A eluate

Recovery eluate + Injections

Start perfusion pump

Collection of skin biopsies

continuous registration of mean arterial blood pressure and heart rate and in the right femoral vein in case an extra vein access was needed. An electrocardiogram was recorded from skin electrodes. Signals were recorded by using a customized computer and software system (PharmLab V6.0, AstraZeneca R&D Gothenburg, Sweden).

The experimental design is illustrated in Figure 3. At t=0 h, VEGF-A mRNA or citrate/saline vehicle was intradermally injected at the intended microdialysis-probe sites as depicted in Figure 4. One h later (i.e., t=1 h), the microdialysis-probes were implanted and perfusion was initiated. Protein-containing eluate was collected during 2-hour periods starting at t=1.5 hours for up to t=7.5 hours after the study drug was injected and handled as described above. At approximately 8 hours after the intradermal injections, the injection sites were harvested and the skin biopsies were stored at -80°C until analyzed. At the end of the experiment, the animals were terminated by a lethal intravenous dose of pentobarbital sodium (Allfetal vet, Omnidea AB, Stockholm, Sweden). The materials and methods section should contain sufficient detail so that all procedures can be repeated. It may be divided into headed subsections if several methods are described.

Six intradermal injections at each intended microdialysis-probe site on the abdomen of the pig were given in two rows with three injections on each side as illustrated in Figure 4. Six 100 kDa linear microdialysis probes, (66 linear catheter & 66 high cut off linear catheter, M Dialysis AB, Hammarby, Stockholm, Sweden) were inserted intradermally according to the instructions provided by the supplier, along one of the two injection rows (Figure 4). The microdialysis probes were perfused with 0.5 μL/min physiological saline (9 mg/mL, Fresenius Kabi AG, Bad Homburg, Germany) and the eluate samples were collected on ice in pre-weighed 0.5 mL tubes (Protein LoBind, Eppendorf AG, Hamburg, Germany). Dead space between the dialysis membrane and the collection tube outlet was about 1.5 μL. The volume of each eluate sample was measured and bovine serum albumin (BSA, A7979, Sigma-Aldrich, St. Louis, MO, USA) in phosphate-buffered saline (pH 7.4, Gibco by Life Technologies, Paisley, UK) was added at 1:1 conditions to a final concentration of 2% albumin. The samples were stored at -80°C until analyzed.

2.3. Assessment of Human VEGF-A Protein in Microdialysis Eluates. The Gyrolab platform was used for determination of levels of expressed human VEGF-A protein in the microdialysis eluate samples from the rabbit. The Gyrolab uses an affinity flow-through format with microstructure wells (Gyros, Uppsala, Sweden). A Gyrolab bioaffy 1000 CD consisting of 96 microstructure wells containing an affinity capture column with streptavidin coated material (Gyros) was used. First, a biotinylated capture polyclonal antibody against human VEGF A (AF-293-NA, R&D systems, Abingdon, UK) was immobilized on the streptavidin column, where samples are flowed through by rotation gravity and the analyte is captured on the antibodies. An Alexa-labelled detection antibody against human VEGF-A (R&D systems) was then flowed through the column and the fluorescence intensity was used for quantification of the ligand. A standard curve was created
using a five-parametric linear fit and the sample concentrations were calculated from the standard curve according to their absorbance. A standard curve ranging from 16.7 pg/mL to 12170 pg/mL was prepared with human VEGF-A165 (293-VE-010, R&D systems) in MSD diluent 9 (Meso Scale Discovery, Rockville, Maryland, USA). Quality controls were prepared from the WHO standard of human VEGF-A165 (National Institute for Biological Standards and Control, Hertfordshire, UK) in MSD diluent 9. All standard, QCs, and samples were mixed 1:1 with Rexxip HN-max (Gyros) before analysis. Lower Limit of Quantification (LLOQ) was 33.4 pg/mL.

Concentrations of VEGF-A165 in the pig microdialysates were determined using a sandwich immunoassay with electrochemical luminescent detection. V-PLEX Human VEGF assay kit (K151RHD, Meso Scale Diagnostics) was used to measure the VEGF-A165 concentration in the microdialysates. Standards were serially diluted in MSD diluents. Samples were diluted 4x with MSD diluents prior to analysis, and the plates were read on the MSD’s Sector Imager 6000. LLOQ was 0.28 pg/mL.

2.5. VEGF-A mRNA Drug Substance and Formulation. VEGF-A mRNA was manufactured by Moderna Therapeutics Inc. as previously described [6, 13]. Briefly, mRNA was synthesized in vitro using 17 polymerase-mediated transcription from a linearized DNA template containing the VEGF-A open reading frame, flanking 5’ and 3’ untranslated regions and a poly-A tail. A Cap1 structure was enzymatically added to the 5’ end to produce the final mRNA. Uridine was completely substituted with N1-methylpseudouridine to reduce potential immunostimulatory activity and to improve VEGF-A protein expression [6] relative to unmodified mRNA. After purification (purity 98.3%), the mRNA was diluted in the desired buffer and frozen at -20°C. A stock solution of VEGF-A mRNA was prepared at 2 mg/mL dilution of the thawed drug substance solution with a buffer solution containing 10 mmol/L sodium citrate dihydrate and 130 mmol/L sodium chloride, pH 6.5. The solution was sterilized by membrane filtration and filled into sterile vials. Further dilutions were done with the same buffer solution.

3. Results

The human VEGF-A protein levels in eluates from the four rabbits (with two inserted probes each, A and B) are presented in Figure 5. Three hours after the injections of VEGF-A mRNA, detectable levels (218±155 pg/mL) of human VEGF-A protein were found in eluates from 3 out of the 8 probes. Correspondingly, at 4 and 5 hours after the injection, VEGF-A protein was detected in the eluate from 5 out of 8 and 5 out of 8 probes, respectively. Despite large variation in the concentrations observed, the protein levels tended to plateau at these time points (369±217 and 360±203 pg/mL, respectively).

Human VEGF-A protein levels in eluates from each of the three individual pigs (with six inserted probes each, labelled A to F) are visualized in Figure 6. Three and a half hours after the injections of VEGF-A mRNA, detectable levels (218±155 pg/mL) of human VEGF-A protein were found in eluates from 3 out of the 8 probes. Correspondingly, at 4 and 5 hours after the injection, VEGF-A protein was detected in the eluate from 5 out of 8 and 5 out of 8 probes, respectively. Despite large variation in the concentrations observed, the protein levels tended to plateau at these time points (369±217 and 360±203 pg/mL, respectively).
hours after the injections, the corresponding results were 62.7±28.4, 357.6±240.6, and 746.3±210.2 pg/mL in eluates from 2 of 6, 3 of 4, and 6 of 6 probes, and 48.8, 529.1±412.1, and 753.0±410.2 pg/mL in eluates from 1 of 6, 3 of 4, and 6 of 6 probes, respectively. Human VEGF-A protein was not detected in eluates from probes implanted at sites injected with citrate/saline vehicle at any time point. In accordance with the VEGF-A concentrations in the microdialysis eluates, the concentration of VEGF-A in the skin biopsies increased dose-dependently (1.0±0.4, 4.6±0.8, and 24.3±6.9 pg/mg for the 24, 120, and 600 µg doses, respectively, Figure 7).

4. Discussion

The present series of experiments demonstrate that intradermal injection of synthetic chemically modified VEGF-A mRNA results in rapid local production of VEGF-A protein as shown by the concentration-dependent increase in VEGF-A protein in eluates from the interstitial microdialysis sampling. We used a human purified mRNA transcript with optimized capping efficiency, UTR, nucleotide design that currently is explored in clinical studies for its safety tolerability and efficacy [6, 10–12]. Recent observations in rats, pigs, and non-human primates indicate that this optimized construct when intracardially or intradermally injected results in rapid, efficient, and sustained transfection of VEGF-A protein [6, 9]. VEGF mRNA uptake and protein expression were followed by in situ hybridization and immunohistochemistry following intracardiac and intradermal injection. Within hours, uptake of mRNA and protein production where demonstrated to occur predominantly in cardiomyocytes, endothelial cells, and adipocytes and VEGF-A protein was produced for several days [6, 9]. Furthermore, the administration was not associated with activation of the innate immune system as evidenced by lack of increase in IL-6 or IL-8 when assessed 3 to 24 hours after injection. In accordance with the recent
observations of efficient transfection and protein production of VEGF-A following intracardiac delivery of VEGF-A mRNA using a biologically compatible buffer thus avoiding use of lipid carriers, we found this citrate-saline formulation effective also when the mRNA was administered in the intradermal space [6]. An additional advantage of the bio-compatible formulation is that the naked mRNA will be tissue specific producing the paracrine protein locally, thus avoiding systemic exposure as any mRNA escaping systemically will promptly be degraded by RNase. Hence, citrate/saline-formulated VEGF-A mRNA administered intradermally or intravenously did not give rise to any systemic levels of VEGF-A in rats or cynomolgus monkeys [6]. Taken together these important improvements have been instrumental in advancing this therapeutic modality into clinical testing to unlock its potential in ischemia-related disease.

In the present study we took the advantage of applying cutaneous microdialysis, which is a semi-invasive method to assess the magnitude and time course of exogenous or endogenous substances in the skin in vivo, to demonstrate production of human VEGF-A from intradermally administered VEGF-A mRNA. Detectable levels of VEGF-A protein were seen in the microdialysis eluates at 3 to 4 hours after the administration and tended to plateau at 6 to 8 hours. This time profile of uptake, translation, and release of modified mRNA-encoded proteins is similar to what has been reported in cardiac tissue homogenates [6, 8]. For practical and ethical reasons, the present study did not allow us to follow the VEGF-A protein production for extended periods of time but, in the heart, a single injection of VEGF-A mRNA was associated for protein production for up to 8 days in the rat [6]. In the present pig experiments, we were able to study the dose-dependency of the injected VEGF-A mRNA in each separate pig. Hence, 3 different doses (24, 120 and 600 μg) were administered and were demonstrated to result in a concentration-dependent increase in protein in the eluates as well as in the skin biopsies harvested at study termination. This is partly in contrast to the apparent lack of dose-dependency seen in cardiac tissue. Hence, Sultana and colleagues did not find any significant differences in the amounts of protein produced in transgenic mice intracardially injected with modified Cre mRNA and, in the study by Carlsson et al., increasing the dose of VEGF-A mRNA 10-fold increased the area under the curve by 1.6-fold only [6, 8]. The reason behind such a saturable uptake process in cardiac tissue and an almost linear protein production in the skin over a wide range of doses is currently unknown but may include saturable effects on the translation and secretion machineries as well.

The doses of VEGF-A mRNA injected in the present study are similar to doses previously administered to mice, rats, and pig and have resulted in functional effects which are in line with the well-known biological effects of VEGF-A on cardiovascular function in general and angiogenesis in particular. Hence, in mice, rats, and pig, single intracardiac injection of VEGF-A mRNA in the setting of acute or sub-acute myocardial infarction has been demonstrated to reduce infarct size, improve left ventricular function, and promote neovascularization [6, 7]. Furthermore, using the multi-parametric photoacoustic microscopy technique, single injections of VEGF-A mRNA in the mouse ear were demonstrated to cause marked and sustained upregulation of the local blood flow near the injection site. In addition, significant capillary angiogenesis and neovascularization 7 to 14 days after the injection of VEGF-A mRNA were noted [9]. However, although injection of recombinant VEGF-A protein was associated with acute cardiovascular effects, the changes were transient, and neovascularization was not observed in these animals.

In summary, we have demonstrated that a single intradermal injection of a modified VEGF-A mRNA in a biocompatible formulation results in a rapid and local production of VEGF-A indicating that this new modality may be of therapeutic benefit in patients with diabetic wounds and ischemic cardiovascular disease.

Data Availability

The data that support the findings of this study are available from AstraZeneca, but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are available however from the authors upon reasonable request and with permission of AstraZeneca.

Conflicts of Interest

All authors are employees of AstraZeneca and may own stock or stock options. There are 3 unpublished provisional applications directed to the subject matter of the paper.

Acknowledgments

This study was funded by AstraZeneca. AstraZeneca develops and markets treatments for cardiovascular and metabolic disorders. Modified VEGF-A mRNA is an investigational medicinal product with no approved indication.

References

[1] S. Ylä-Herttuala, T. T. Rissanen, I. Vajanto, and J. Hartikainen, “Vascular endothelial growth factors: biology and current status of clinical applications in cardiovascular medicine,” Journal of the American College of Cardiology, vol. 49, no. 10, pp. 1015–1026, 2007.
[2] K. O. Lui, L. Zangi, and K. R. Chien, “Cardiovascular regenerative therapeutics via synthetic paracrine factor modified mRNA,” Stem Cell Research, vol. 13, no. 3, pp. 693–704, 2014.
[3] K. R. Chien, L. Zangi, and K. O. Lui, “Synthetic chemically modified mRNA (ModRNA): Toward a new technology platform for cardiovascular biology and medicine,” Cold Spring Harbor Perspectives in Medicine, vol. 5, no. 1, Article ID a04035, 2015.
[4] U. Sahin, K. Karikó, and Ö. Türeci, “mRNA-based therapeutics—developing a new class of drugs,” Nature Reviews Drug Discovery, vol. 13, no. 10, pp. 759–780, 2014.
[5] R. Kedmi, N. Ben-Arie, and D. Peer, “The systemic toxicity of positively charged lipid nanoparticles and the role of Toll-like receptor 4 in immune activation,” Biomaterials, vol. 31, no. 26, pp. 6867–6875, 2010.
[6] L. Carlsson, J. C. Clarke, C. Yen et al., “mRNA improves cardiac function after intracardiac injection one week post-myocardial infarction in swine,” *Molecular Therapy - Methods & Clinical Development*, vol. 9, pp. 330–346, 2018.

[7] L. Zangi, K. O. Lui, A. Von Gise et al., “Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction,” *Nature Biotechnology*, vol. 31, no. 10, pp. 898–907, 2013.

[8] N. Sultana, A. Magadum, Y. Hadas et al., “Optimizing Cardiac Delivery of Modified mRNA,” *Molecular Therapy*, vol. 25, no. 6, pp. 1306–1315, 2017.

[9] N. Sun, B. Ning, K. M. Hansson et al., “Modified VEGF-A mRNA induces sustained multifaceted microvascular response and accelerates diabetic wound healing,” *Scientific Reports*, vol. 8, no. 1, Article ID 17509, 2018.

[10] L. M. Gan, M. Lagerström-Fermér, L. Carlsson et al., “Intradermal delivery of modified mRNA encoding VEGF-A in patients with type 2 diabetes,” *Nature Communications (accepted manuscript)*, 2019.

[11] “Assessment of the safety, tolerability and pharmacodynamics after administration of one dose of AZD8601 to male patients with type II diabetes mellitus (T2DM),” ClinicalTrials.gov Identifier NCT02935712.

[12] “AZD8601 study in CABG patients,” ClinicalTrials.gov Identifier NCT03370887.

[13] K. Bahl, J. J. Senn, O. Yuzhakov et al., "Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses," *Molecular Therapy*, vol. 25, no. 6, pp. 1316–1327, 2017.